• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Radioimmunoconjugates for treating cancer: recent advances and current opportunities
【24h】

Radioimmunoconjugates for treating cancer: recent advances and current opportunities

机译：用于治疗癌症的放射免疫缀合物：最近的进展和当前的机会

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Radioimmunoconjugates have been used for 30years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours.Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives. Then, the authors summarize the development of radionuclides, the use of recombinant antibodies, pretargeting approaches, and dose fractionation techniques, providing opportunities for both therapeutic and diagnostic applications.Expert opinion: Radioimmunoconjugates used in nuclear medicine have entered a new era of development. These advances give rise to a variety of opportunities in the management of various cancers, where the radiolabelled antibodies may be particularly useful in immuno-specific phenotypic imaging e.g. companion diagnostics. Concerning therapeutic applications, radioimmunoconjugates have demonstrated their efficacy in the treatment of both haematological malignancies and solid tumours. Recent procedural developments are of great interest in optimising oncological targeted therapies. In the field of cancer theranostics, we believe that radioimmunoconjugated compounds are likely to play a large part in near future.
机译：简介：放射免疫缀合物已被用于30年诊断和治疗癌症。多年来，使用这些治疗工具的使用仅限于血液学疾病，例如非霍奇金淋巴瘤，因为它们只对固体肿瘤的效果较为效果。覆盖：最近，几项策略恢复了潜在的治疗申请用于放射免疫缀合物。在本综述中，作者审查了免疫工程的进展，以发展单克隆抗体等新工具及其衍生物。然后，作者总结了放射性核素，使用重组抗体，预靶向方法和剂量分馏技术的发育，为治疗和诊断申请提供了机会.Pert意见：核医学中使用的放射免疫缀合物进入了新的发展时代。这些进步引起各种癌症的各种机会，其中放射性标记的抗体在免疫特异性表型成像中可能特别有用。伴侣诊断。关于治疗应用，放射免疫缀合物已经证明了它们在治疗血液恶性肿瘤和实体瘤中的疗效。最近的程序发展对优化肿瘤有针对性的疗法有益。在癌症治疗癌症领域，我们认为放射免疫谐波化合物可能在不久的将来发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号